Centogene facility adds sequencing platform, 2/17
February 2017—Centogene, a genetics company focused on the early diagnosis of rare hereditary disorders, has introduced the Illumina HiSeq X whole genome sequencing platform …
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Liquid biopsy system, 2/17
February 2017—WaveSense introduced its nRichDX system for the bulk isolation of target cells and nucleic acids from liquid biopsies. The nRichDX uses the company’s proprietary paramagnetic bead technology to enable the capture of circulating tumor cells and cell-free DNA or cell-free RNA in quantities sufficient for analysis by next-generation sequencing and PCR techniques.
Trovagene, Boreal Genomics strategic partnership, 2/17
February 2017—Trovagene has entered into a long-term supply and distribution agreement with Boreal Genomics in which they will merge their respective technologies to co-develop urine and blood ctDNA assay kits. The companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine, and low-cost urine and blood ctDNA assay for next-generation sequencing platforms run by laboratories of research institutions, cancer centers, and service facilities around the world.
All-in-one library prep kit, 2/17
February 2017—Qiagen launched the QIAseq cfDNA All-in-One kit, combining cell-free DNA extraction and library preparation in a dedicated solution for liquid biopsy analysis on next-generation sequencing platforms. The kit integrates with Qiagen’s PAXgene Blood ccfDNA tube as well as with the company’s bioinformatics workflow for cfDNA, creating a streamlined testing solution that aims to allow faster, more convenient, and reliable analysis of cell-free DNA from sample collection to interpreted result.
Fully automated fluorescent multiplex procedure, 2/17
February 2017—Roche launched its Discovery 5-Plex procedure and reagents for immunohistochemistry research applications. This is the first pre-optimized, fully automated multiplex procedure available on the Ventana Discovery Ultra instrument.
ARUP Labs, ASI enter collaboration, 2/17
February 2017—Applied Spectral Imaging has entered into a collaboration with ARUP Laboratories to facilitate the development and commercialization of advanced digital pathology solutions, enhancing workflow efficiencies and simplifying the management and accessibility of clinical data.
Fully automated IHC multiplexing kits, 2/17
February 2017—PerkinElmer’s Opal Multicolor Immunohistochemistry products for use with Leica Biosystems’ fully automated Bond RX research staining platform is now available. The kits can visualize up to six biomarkers and a nuclear counterstain on a single tissue section with next-day results.
FDA clears Vitros automation solutions, 1/17
January 2017—Ortho Clinical Diagnostics announced that the Food and Drug Administration has cleared its Vitros Automation Solutions for use with Ortho’s Vitros chemistry, immunodiagnostics, and integrated systems.
Single-cell analysis instrument, 1/17
January 2017—Qiagen launched its QIAscout, a novel instrument for isolation of viable single cells from samples to enable single-cell analysis for next-generation sequencing, polymerase chain reaction, and other downstream applications.
Selective and differential medium, 1/17
January 2017—Hardy Diagnostics announced its new product, C Diff Banana Broth, which is recommended as a selective detection broth for the recovery of Clostridium difficile from environmental samples. Its name is derived from the color change reaction when C. diff is present; the broth changes from a deep red, indicating a negative reaction, to a milky yellow, indicating a positive reaction.